Monograph Details
|
|
Central Nervous System
> Parkinsonism
|
|
PARCOPA 25mg/100mg |
| Manufacturer |
|
Schwarz Pharma, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Dopa-decarboxylase inhibitor + dopamine precursor. |
| Generic Name |
|
Carbidopa 25mg, levodopa 100mg; orally-disintegrating tabs; mint flavor; contains phenylalanine. |
| Also |
• PARCOPA 10mg/100mg
• PARCOPA 25mg/250mg
|
| Indications |
|
Parkinsonism. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Discontinue levodopa at least 12 hrs before starting Parcopa. Dissolve tabs on tongue. ≥18yrs: initially one 25/100 tab 3 times daily, or one 10/100 tab 3–4 times daily; increase every 1–2 days up to either 2 tabs of 25/100 or 2 tabs of 10/100 4 times daily. Patients taking levodopa >1500mg/day: initially one 25/250 tab 3–4 times daily; usual max carbidopa 200mg/day. |
| Contraindications |
|
During or within 14 days of nonselective MAOIs. Narrow-angle glaucoma. Undiagnosed skin lesions. History of melanoma. |
| Precautions |
|
Severe cardiovascular or pulmonary disease. Asthma. Renal, hepatic, or endocrine disorders. History of peptic ulcer or MI with residual arrhythmias. Suicidal tendencies. Psychosis. Orthostatic hypotension. Chronic wide-angle glaucoma. Monitor renal, hepatic and cardiovascular function, intraocular pressure, blood counts. May stain body fluids. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. Antagonized by phenothiazines, butyrophenones, risperidone, phenytoin, papaverine, isoniazid; possibly iron, high protein diets, excessive gastric acidity. Orthostatic hypotension with selegiline, antihypertensives. May be affected by metoclopramide. Hypertension, dyskinesia with tricyclics. May cause false (+) urinary ketone or Coombs test or false (–) urinary glucose (glucose oxidase) test. |
| Adverse Reactions |
|
Dyskinesias, GI upset, CNS disturbances (eg, hallucinations, confusion, depression, dizziness, headache, insomnia, somnolence), syncope, hypo- or hypertension, dyspnea, on-off phenomena, blepharospasm (may indicate excess dose), urine discoloration, lab abnormalities; rare: neuroleptic malignant syndrome. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
